Critical Contrast: Renalytix (NASDAQ:RNLX) versus Exact Sciences (NASDAQ:EXAS)

Renalytix (NASDAQ:RNLXGet Rating) and Exact Sciences (NASDAQ:EXASGet Rating) are both computer and technology companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

Earnings and Valuation

This table compares Renalytix and Exact Sciences’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Renalytix $1.49 million 43.15 -$34.72 million ($0.63) -2.73
Exact Sciences $1.77 billion 4.07 -$595.63 million ($4.23) -9.61

Renalytix has higher earnings, but lower revenue than Exact Sciences. Exact Sciences is trading at a lower price-to-earnings ratio than Renalytix, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for Renalytix and Exact Sciences, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Renalytix 0 0 4 0 3.00
Exact Sciences 0 2 10 0 2.83

Renalytix currently has a consensus target price of $12.60, suggesting a potential upside of 632.56%. Exact Sciences has a consensus target price of $69.14, suggesting a potential upside of 70.09%. Given Renalytix’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Renalytix is more favorable than Exact Sciences.

Risk & Volatility

Renalytix has a beta of 1.96, indicating that its stock price is 96% more volatile than the S&P 500. Comparatively, Exact Sciences has a beta of 1.37, indicating that its stock price is 37% more volatile than the S&P 500.


This table compares Renalytix and Exact Sciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Renalytix -1,770.47% -89.48% -75.58%
Exact Sciences -37.90% -22.07% -11.19%

Insider and Institutional Ownership

15.2% of Renalytix shares are held by institutional investors. Comparatively, 91.0% of Exact Sciences shares are held by institutional investors. 21.6% of Renalytix shares are held by insiders. Comparatively, 1.3% of Exact Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.


Renalytix beats Exact Sciences on 8 of the 14 factors compared between the two stocks.

About Renalytix

(Get Rating)

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.

About Exact Sciences

(Get Rating)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Receive News & Ratings for Renalytix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renalytix and related companies with's FREE daily email newsletter.